Combined evidence from two clinical trials has confirmed the safety and efficacy of Boehringer Ingelheim’s OFEV (nintedanib) in slowing disease progression and greatly reducing acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF), according to a study in Respiratory Medicine.

Combined data revealed fewer patients experienced acute exacerbations in the OFEV treatment group compared to the placebo group (4.6% vs 8.7%), OFEV reduced the risk of an acute exacerbation by 47% compared to placebo, and improve forced vital capacity (FVC).

Patients receiving OFEV had a 30% reduced risk of dying from any cause, a 43% reduced risk of on-treatment mortality, and a 38% reduction in the risk of dying from an acute exacerbation or any other respiratory cause.